MEM (ASX) MEM Discussion

Originally posted by Quest09: ↑

Looking forward to an update on the Heranova China study and potential commercial roll-out agreement. As per the below, there seems to be sooo much potential in this deal in particular.

"MEM is pleased to announce the commencement of in vitro utilisation testing of its Felix™ System in China, as part of the agreement with Heranova Lifesciences HK Limited........."

"Subject to positive results, Memphasys and Heranova will work towards an exclusive distribution agreement with the option of licensing and manufacturing the Felix TM System in the Territory, and finance of clinical trials and applications for NMPA Registration in the China."
"Results to pave the way to access China’s IVF market, valued at USD 5.37 billion in 2023, is projected to grow to USD 9.04 billion by 2030."

Expand

Originally posted by Quest09: ↑

China is facing a significant population decline issue.

The population has been shrinking for several years, with the fertility rate falling well below the replacement level of 2.1 births per woman. This decline is attributed to factors like the legacy of the one-child policy, rising living costs, and changing societal attitudes among younger generations.
The Chinese government has introduced various measures to address this challenge. These include:
Policy Changes: The one-child policy was relaxed to allow two children in 2016 and three children in 2021.
Financial Incentives: Subsidies for childbirth, housing support, and increased borrowing limits for families with multiple children.
Childcare Support: Establishing childcare service centers and expanding maternity insurance to include flexible and rural workers.
Healthcare Improvements: Covering labor pain relief and assisted reproductive technologies under medical insurance.

With headlines like the below, it seems that a MEM deal could progress very quickly in the Chineses market:

Expand

Originally posted by Quest09: ↑

The Heranova trial in China is the most exciting aspect of MEM's current and future prospects IMO.

China is the one of the biggest markets globally for IVF, if not the biggest, and as per the above attached posts, China has active government policies which are promoting child birth within the declining population of China.

IMO, all things seem well aligned for MEM and Heranova to provide Felix as commercial solution to China's declining population problem. Interestingly, China is also globally known as a factory production powerhouse....and can produce products at a relatively cheap cost by global standards......so any commercial agreement between MEM and Heranova could also easily include the production of the Felix System in China at a relatively inexpensive cost of production (so many factories in China looking for new customers).

The Heranova study aims to test 50 patients in China and has been ongoing now for about 3 months. I can't imagine it would take long to complete a trial of 50 patients in China, considering they have such a large population (1.4 billion people).

IMO, an update on the Heranova agreement could be just around the corner......and could be potentially transformative for MEM as a company.

Expand

Another interesting prospect which we could receive an update on at any time is the Brazilian market entry via Lab Androscience.

Clinical trial was due to run for about three months...which is now near completion....and additionally Lab Androscience will also now have the MEM clinical trial results to review, which is of course a much bigger trial.

From the announcement in February:
"sophisticated investors associated with Laboratorio Androscience have expressed an interest in supporting Memphasys’ activities in the country............... they are likely to invest to facilitate market entry via a licensing arrangement...........the Company (MEM) will keep the market fully informed should a proposal be received that warrants disclosure."